# EDGAR Filing Document

**Accession Number:** 0001840574
**File Stem:** 9999999995-25-002366
**Filing Date:** 2025-7
**Character Count:** 1347
**Document Hash:** 3055c2084caea733a29c300e07a1fc21
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**9999999995-25-002366.hdr.sgml**: 20250729

**ACCESSION NUMBER**: 9999999995-25-002366

**CONFORMED SUBMISSION TYPE**: EFFECT

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250728

**DATE AS OF CHANGE**: 20250729

**EFFECTIVENESS DATE**: 20250728

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Verve Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001840574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 824800132
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** EFFECT
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-267578
- **FILM NUMBER:** 251157378

**BUSINESS ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215
- **BUSINESS PHONE:** (978) 501-3026

**MAIL ADDRESS:**
- **STREET 1:** 201 BROOKLINE AVENUE
- **STREET 2:** SUITE 601
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02215

### UNITED STATES
### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## Notice of Effectiveness

**Date:** July 28, 2025

**Accession Number:** 0001193125-25-165532

**Form Type:** POS AM

---

**CIK:** 0001840574

**Company Name:** Verve Therapeutics, Inc.

**File Number:** 333-267578